ILCA’s First Annual Conference · New York, United States ... Enrique Lopez Hänninen2, Birgit...

PRE-CONFERENCEFINAL PROGRAMME

5 - 7 October 2007 ILCA’s First Annual ConferenceInaugurating the International Liver Cancer Association:

Gran Hotel Princesa Sofia, Barcelona-Spain

C o n v e n i n g a c o m m u n i t y

d e d i c a t e d t o a d v a n c i n g

r e s e a r c h i n t h e p a t h o g e n e s i s ,

p r e v e n t i o n a n d t r e a t m e n t

o f l i v e r c a n c e r

www. i lca-on l ine .org

I L C A ’ S A N N U A L C O N F E R E N C E , 2 0 0 72

I L C A ’ S A N N U A L C O N F E R E N C E , 2 0 0 7 3

An Invitation to Attend

An invitation from ILCA’s President and ExecutiveSecretary

On behalf of the recently founded International Liver Cancer Association (ILCA), it is our pleasureto invite you to attend our very first Annual Conference that not only marks the launch of aninsightful new generation of meetings pioneering a transversal approach to liver cancer, but willset the stage and pace for ILCA Annual Conferences to come.

This pre-conference Final Programme provides you with a detailed overview of just some of themany highlights that await ILCA members, friends, colleagues and peers in Barcelona, Spain, 5-7 October.

Powerful reasons for you to attend include the two translationally and clinically focused State ofthe Art Sessions, to be delivered by Curtis Harris and Masatoshi Makuuchi respectively, as well asour two core Symposia that will deliver cutting edge advancement at the research and treatmentlevels. Attracting basic researchers, physicians and allied professionals alike, the underlying keysymposia themes centre on and around signal transduction pathways in liver tumours and futureprospects in clinical outcomes in liver cancer.

The five specially devised General Sessions – consisting of selected findings to be delivered asoral communications - will offer all participants an unparalleled opportunity to update on the latestdevelopments in molecular pathogenesis, cell biology and translational research; clinical trialsand treatment research; epidemiology, staging and prognosis; and diagnostic imaging andmolecular pathology.

In the hope that this pre-conference Final Programme will draw your attendance to our inauguralILCA Annual Conference, we consequently look forward to welcoming you to Barcelona for whatpromises to be an unforgettable meeting.

Jordi Bruix, M.D. Josep M. Llovet, M.D.President Executive Secretary

Jordi Bruix

Josep M. Llovet

Friday, 5 October

Speaker: Curtis Harris, Bethesda (USA)

Saturday, 6 October

General Session 1: Clinical trials and treatment (Curative) Lleida/Tarragona

17.00 - 18.30 General Session 4: Clinical trials and treatment (RCTs and new therapies) Lleida/Tarragona

16.30 - 17.00 Coffee Break Sitges/Rosas & Baleares

15.00 - 16.30 Business Meetings for ILCA Members Lleida/Tarragona

13.00 - 15.00 Industry Symposium (Bracco)Focal liver lesions - The key role of contrast-enhanced UltraSound (CEUS) modality for diagnosis and early assessment of treatment efficacy

Lleida/Tarragona

Sitges/Rosas & BalearesCoffee Break16.00 - 16.30

11.00 - 13.00 Symposium: Future prospects in clinical research in HCC Lleida/Tarragona

10.30 - 11.00 Coffee Break Sitges/Rosas & Baleares

09.00 - 10.30 General Session 3: Molecular pathogenesis (Signalling and novel targets) Lleida/Tarragona

19.30 - 20.30 Welcome Reception Sitges/Rosas & Baleares

18.00 - 19.30 Industry Symposium (Bayer Schering Pharma) Recent advances with targeted therapies: a new era in the management ofhepatocellular carcinoma

Lleida/Tarragona

16.30 - 18.00 General Session 2: Molecular pathogenesis (Genomics) Lleida/Tarragona

15.00 - 16.00 The Translational Lecture: Chronic inflammation and cancer development Lleida/Tarragona

13.30 - 15.00

13.15 - 13.30 Opening Ceremony Lleida/Tarragona

11.30 - 13.15 Industry Symposium (Biocompatibles)TACE in HCC: A multi-disciplinary overview

Lleida/Tarragona

Programme at a Glance



Sunday, 7 October

Speaker: Masatoshi Makuuchi, Tokyo (Japan)

Participants will be able to visit the Poster Exhibition on Friday, 5 October and Saturday, 6 October, from 09.00 - 18.00.A list of posters on display can be found on page 16.

To register, please visit www.ilca-online.org(select Annual Conferences - Annual Conference 2007 - Registration Open)

Lleida/Tarragona

Lleida/TarragonaClosing Remarks14.00 - 14.10

Lleida/Tarragona

Lleida/Tarragona

Lleida/Tarragona

Sitges/Rosas & Baleares

12.30 - 14.00 General Session 5: Diagnosis, staging and prognosis

11.30 - 12.30 The Clinical Lecture: Past, present and future of surgical management of HCC

11.00 - 11.30 Coffee Break

09.00 - 11.00 Symposium: Signal transduction pathways in liver tumors

08.30 - 09.00 IARC's research agenda for combating liver cancer worldwide

General Sessions

State of the Art Sessions

Symposia

Industry Symposia

Other Meetings


Scientific Programme

Friday, 5 October Room

Lleida/Tarragona

For futher details see pages 20/21 - Industry Symposia Highlights

Lleida/TarragonaChairs: M. Colombo (Italy), M. Schwartz (USA)

13.30 - 13.45 • O-001 Living donor liver transplantation for hepatocellular carcinoma;

experience with 653 cases in Japan

Authors: Tsuyoshi Shimamura*1,H Furukawa1, T Suzuki1,

M Taniguchi1, K Yamashita1, T Kamiyama1, M Matsushita1, S Todo1

1Division of Organ Transplantation, Hokkaido University Hospital, Sapporo, Japan

13.45 - 14.00 • O-002 Grading of microvascular invasion by hepatocellular carcinoma

treated by hepatic resection

Authors: Sasan Roayaie*1, Mostafa Gaabour1, Iris Blume1,

Swan Thung1, Josep Llovet1, Myron Schwartz1

1Mount Sinai Liver Cancer Program, Department of Surgery,

New York, United States

14.00 - 14.15 • O-003 Surgical resection for hepatocellular carcinoma with portal vein

tumor thrombus

Authors: Kiyoshi Hasegawa*1, Norihiro Kokudo1, Hiroshi Imamura1,

Takeaki Ishizawa1, Yosuke Inoue1, Michiro Takahashi1, Taku Aoki1,

Yoshifumi Beck1, Keiji Sano2, Yasuhiko Sugawara2,

Masatoshi Makuuchi2

1Hepato-Biliary-Pancreatic Surgery Division, University of Tokyo,

2Department of Surgery, Japanese Red Cross Medical Center,

Tokyo, Japan

14.15 - 14.30 • O-004 Liver resection for intrahepatic cholangiocarcinoma

Authors: Sven Jonas*1, Armin Thelen1, Christoph Benckert1,

Enrique Lopez Hänninen2, Birgit Rudolph3, Johann Pratschke1,

Peter Neuhaus1

1General, Visceral and Transplantation Surgery, 2Radiology, Charité

Campus Virchow Klinikum, 3Pathology, Charité, Berlin, Germany

Industry Symposium (Biocompatibles)

TACE in HCC: A multi-disciplinary overview

Opening Ceremony

13.30 - 15.00 General Session 1: Clinical trials and treatment (Curative)

13.15 - 13.30 Lleida/Tarragona

11.30 - 13.15

General Sessions


Symposia

Industry Symposia

Other Meetings


14.30 - 14.45 • O-005 Predictors of dropout from transplant waiting list among patients

listed for hepatocellular carcinoma using the UNOS/OPTN

database

Authors: Carlos Romero Marrero*1, Jorge Marrero1, Sherry Fu1,

Veena Thyagarajan1

1Medicine, University of Michigan, Ann Arbor, United States

14.45 - 15.00 • O-006 Liver transplantation as primary therapy for hepatocellular

carcinoma in non-cirrhotic livers

Authors: Hynek Mergental*1, D. Castaing2, R. Adam2, B.G. Ericzon3, J.L. Klempnauer4,

P. Kalicinski5, C. Broelsch6, A. Köningsrider7, S. Friman8, B. de Hemptinne9, J. Pirenne10,

G. Mantion11, Y. PLe Treut12, B. van Hoek13, C.F. Sellez14, X. Rogiers15, F. Löhe16, P. Wolf17,

O. Detry18, V. Mazzaferro19, R. J. Porte1

1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2,

Hôpital Paul Brousse, Villejuif, France, 3, Huddinge Hospital, Huddinge, Sweden, 4,

Medizinische Hochschule, Hannover, Germany, 5, Children's Memorial Health Institute,

Warsaw, Poland, 6, Universitatsklinikum Essen, Essen, 7, Universitatsklinik Tübingen,

Tübingen, Germany, 8, Sahlgrenska University Hospital, Gothenburg, Sweden, 9, Universitair

Ziekenhuis Ghent, Ghent, 10, Universitaire Ziekenhuizen Leuven, Leuven, Belgium, 11, Hôpital

Jean Minjoz, Besancon, 12, Hôpital de la Conception, Marseille, France, 13, Leiden University

Medical Center, Leiden, Netherlands, 14, Hospital Juan Canalejo, La Coruna, Spain, 15,

Universitatskrankenhaus Eppendorf, Hamburg, 16, Klinikum der Universitat München-

Grosshadern, München, Germany, 17, Hôpital Hautepierre, Strasbourg, France, 18, University

Hospital, Liege, Belgium, 19, Istituto Nazionale Tumori, Milano, Italy

Lleida/TarragonaChair: Gregory J. Gores, Rochester (USA)Speaker: Curtis Harris, Bethesda (USA)

15.00 - 16.00 The Translational Lecture: Chronic inflammation and cancer development

Friday, 5 October


Lleida/TarragonaChairs: M.A. Buendia (France), S. Thorgeirsson (USA)

16.30 - 16.45 • O-007 A new prognostic subtype of hepatoblastoma defined by specific

gene expression profile and genomic aberrations

Authors: Carolina Armengol*1, Cairo Stefano3, Aurélien de Reyniès3,

Emilie Thomas3, Veronique Laithier4, Laurence Brugières5, Marco

Pontoglio6, Monique Fabre7, Marie Annick Buendia2

1Unite d'Oncogenèse et Virologie Moléculaire, 2Unite d'Oncogenèse et Virologie

Moléculaire, Institut Pasteur, 3Informatic Department, Ligue Nationale contre le

Cancer, Paris, Onco-Hématologie pédiatrique, CHU de Besançon, Besançon,

5Pediatric Department, Institut Gustave Roussy, Villejuif, 6Gene Expression and

Disease Unit. Centre National de la Recherche Scientifique (CNRS) FRE 2850,

Institut Pasteur, Paris, 7Anatomie et Cytologie

Pathologiques, CHU de Bicêtre, Le Kremlin-Bicêtre, France

16.45 - 17.00 • O-008 Expression of stemness gene Bmi-1 in hepatocellular carcinoma

Author: Michiie Sakamoto*1

1Pathology, Keio University School of Medicine, Tokyo, Japan

17.00 - 17.15 • O-009 Integrated profiling of DNA and RNA alterations in hepatitis C

virus positive hepatocellular carcinomas

Authors: Derek Chiang*1, Augusto Villaneuva2, Judit Peix2, Philippa

Newell2, Elisa Wurmbach2, Diana Donovan3, Rameen Beroukhim1,

Gad Getz1, Sasan Roayaie2, Myron Schwartz2, Vincenzo Mazzaferro4,

Jordi Bruix5, Samuel Waxman2, Scott Friedman2, Massimo Loda3,

Azra Ligon3, Matthew Meyerson3, Josep Llovet2

1Cancer Program, Broad Institute of Harvard and MIT, Cambridge,

2Mount Sinai Liver Cancer Program, Mount Sinai School of

Medicine, New York, 3Pathology, Brigham and Women's Hospital,

Boston, United States, 4Digestive Surgery and Liver Transplantation

Unit, National Cancer Institute, Milan, Italy, 5Barcelona Clinic Liver

Cancer group, University of Barcelona, Barcelona, Spain

17.15 - 17.30 • O-010 Survival gene signature for hepatocellular carcinoma (HCC) from

high-throughput profiling of informative transcriptome in

archived paraffin-embedded tissue

16.30 - 18.00 General session 2: Molecular pathogenesis (Genomics)

Friday, 5 October

Authors: Yujin Hoshida*1, Masahiro Kobayashi2, Augusto Villanueva3,

Amy Camargo1, Supriya Gupta1, Jamie Moore1, Matthew J. Wrobel1,

Jim Lerner1, Michael Reich1, Jennifer A. Chan1, Kenji Ikeda2,

Masashi Hashimoto2, Goro Watanabe2, Sasan Roayaie3, Myron

Schwartz3, Swan Thung3, Stacey Gabriel1, Vincenzo Mazzaferro4,

Jordi Bruix5, Scott Friedman3, Hiromitsu Kumada2, Josep M. Llovet3,

Todd R. Golub1

1Broad Institute, Massachusetts Institute of Technology and

Harvard University, Cambridge, United States, 2Department of

Gastroenterology, Toranomon Hospital, Tokyo, Japan, 3Mount Sinai

Liver Cancer Program, Mount Sinai School of Medicine, New York,

United States, 4, National Cancer Institute, Milan, Italy, 5Barcelona

Clinic Liver Cancer Group, Hosp Clínic Barcelona, Tokyo, Spain

17.30 - 17.45 • O-011 miRNA expression profiling in benign and malignant liver tumors:

correlations with clinical and genetic features

Authors: Yannick Ladeiro*1, Gabrielle Couchy1,

Jessica Zucman-Rossi1

1 CEPH, Inserm U674, Paris, France

17.45 - 18.00 • O-012 A unique metastasis-related microRNA expression signature is

a prognostic indicator of survival and recurrence in

hepatocellular carcinoma

Authors: Anuradha Budhu*1,Hu-Liang Jia1, Marshonna Forgues1,

Chang-Gong Liu2, David Goldstein3, Amy Liu4, Krista A. Zanetti1,

Qing-hai Ye5, Lun-Xiu Qin5, Carlo M. Croce2, Zhao-You Tang5,

Xin W. Wang1

1Laboratory of Human Carcinogenesis, National Cancer Institute,

Bethesda, 2Molecular Virology, Immunology, and Medical Genetics

and Comprehensive Cancer Center, Ohio State University,

Columbus, 3Office of Science and Technology Partnerships,

National Cancer Institute, Bethesda, 4EMMS Corporation, EMMS

Corporation, Rockville, United States, 5LiverCancer Institute and

Zhongshan Hospital, Fudan University, Shanghai, China

Lleida/Tarragona


18.00 - 19.30 Industry Symposium (Bayer Schering Pharma) Recent advances with targeted therapies: a new era in the management of hepatocellular carcinoma


& Sitges

Friday, 5 October

General Sessions


Symposia

Industry Symposia

Other Meetings


Saturday, 6 October Room

Lleida/TarragonaChairs: J.F. Dufour (Switzerland), M. Otzurk (Turkey)

09.00 - 09.15 • O-013 Stromal regulation of hepatocarcinogenesis:

PDGF receptors as a target for therapy

Authors: Claudia Mitchell*1, Nelson Fausto1, Jean Campbell2, Matthew Yeh1

1Pathology, University of Washington, Seattle, United States, 2Pathology,

University of Washington, Seattle

09.15 - 09.30 • O-014 Molecular and functional dissection of the insulin-like growth factor (IGF)-II signalling pathway in human hepatocarcinogenesis

Authors: Kay Breuhahn*1,Tanja Nussbaum1, Volker Ehemann1, Eduard Ryschich2,

Akmal Khamidjanov2, Peter Schirmacher1, Kai Breuhahn1

1Institute of Pathology, 2Department of Surgery, University Hospital Heidelberg,

Heidelberg, Germany

09.30 - 09.45 • O-015 Smad interacting protein SIP1 acts as a negative regulator of

growth in hepatocellular carcinoma cells

Authors: Ayca Arslan-Ergul*1,Sevgi Bagislar1, Nuri Ozturk2, Serif Senturk1, Mehmet Ozturk1

1Molecular Biology and Genetics, Bilkent University, Ankara, Turkey, 2Biochemistry and

Biophysics Dept., University of North Carolina, Chapel Hill, United States

09.45 - 10.00 • O-016 Homozygous deletion of p53 induces liver cancer exhibiting

Authors: André Lechel*1,Yvonne Begus*1, Peter Schirmacher2, K.Lenhard Rudolph1

1Gastroenteroloy, Medical School Hannover, Hannover, 2Pathology,

University of Heidelberg, Heidelberg, Germany

10.00 - 10.15 • O-017 Integrative genomic analysis of PI3K/AKt/mTOR pathway in

hepatocellular carcinoma: clinical outcome implications

Authors: Augusto Villanueva*1, Derek Y. Chiang2, Philippa Newell1, Judit Peix1,

Yujin Hoshida2, Stijn Van Laarhoven1, Swan Thung3, Sasan Roayaie4, Clara Alsinet5, Isabel

Fiel3, Myron Schwartz4, Samuel Waxman6, Jordi Bruix5, Vinzenzo Mazzaferro7, Todd Golub2,

Scott L. Friedman1, Matthew Meyerson2, Josep M. Llovet1,5

1Liver Diseases, Mount Sinai School of Medicine, New York, 2Cancer Program,

Broad Institute of MIT and Harvard, Cambridge, 3Pathology, 4Surgical Oncology, Mount

Sinai School of Medicine, New York, United States, 5Liver Unit, Hospital Clinic, Barcelona,

General Session 3: Molecular pathogenesis (Signalling and novel targets) 09.00 - 10.30

Saturday, 6 October


Spain, 6Oncological Sciences, Mount Sinai School of Medicine, New York, United States,

7Surgery, Instituto Nazionale dei Tumori, Milan, Italy

10.15 - 10.30 • O-018 Sorafenib inhibits the Raf/MEK/ERK pathway and angiogenesis,

induces apoptosis and produces robust efficacy in preclinical

models of hepatocellular carcinoma (HCC)

Authors: Scott Wilhelm*1,Lila Adnane1, Mark Lynch1

1Global Scientific Communications Oncology, Bayer Pharmaceuticals Corporation,

West Haven, United States

Lleida/Tarragona

Chairs: Pierre-A. Clavien, Zurich (Switzerland), Ding-Shinn Chen, Taipei (Taiwan)

• Review of current guidelines for clinical practice and research

Jordi Bruix, Barcelona (Spain)

• New markers for screening and diagnosis

Laura Beretta, Seattle (USA)

• Emerging molecular targeted therapies

Andrew X. Zhu, Boston (USA)

• Principles of trial design in HCC research

Josep M. Llovet, Barcelona (Spain) - New York (USA)

Lleida/Tarragona


Lleida/Tarragona15.00 - 16.30 Business Meetings for ILCA Members

13.00 - 15.00 Industry Symposium (Bracco)Focal liver lesions - The key role of contrast-enhanced UltraSound (CEUS) modality for diagnosis and early assessment of treatment efficacy

11.00 - 13.00 Symposium: Future prospects in clinical research in HCC

General Sessions


Symposia

Industry Symposia

Other MeetingsSaturday, 6 October


Lleida/TarragonaChairs: M. Beaugrand (France), J. Furuse (Japan)

17.00 - 17.15 • O-019 Activity of sunitinib in patients with advanced hepatocellular

carcinoma (HCC): an international phase II trial

Authors: Sandrine Faivre*1, Eric Raymond1, Francoise Degos1,

Jean Y. Douillard2, Eveline Boucher3, Ho Y. Lim4, Jun S. Kim5, Silvana

Lanzalone6, Maria J. Lechuga6, Laurie J. Sherman7,

Ann-Lee Cheng8

1Service Inter Hospitalier de Cancerologie Bichat-Beaujon, Hôpital Beaujon, Clichy,

2Service Oncologie Medicale, Centre Rene Gauducheau, St-Herblain, 3Hopital

Pontchaillou, University Hospital, Rennes, France, 4Division of

Hematology/Oncology, Samsung Medical Center, 5Guro Hospital, Korea University,

Seoul, South Korea, 6Clinical Research Oncology, Pfizer, Milan, Italy, 7Oncology-

Medicine Development Center, GlaxoSmithKline, Collegeville, United

States,8Department of Internal Medicine, National Taiwan

University Hospital, Taipei, Taiwan

17.15 -17.30 • O-020 Long acting octreotide in the treatment of advanced

hepatocellular carcinoma and overexpression of somatostatin

receptors. A randomized placebo-controlled trial

Authors: Dimitrios Dimitroulopoulos*1,Dimitrios Xinopoulos1,

Klisthenis Tsamakidis1, Efthimios , Andriotis2, Athanasios

Zisimopoulos3, Aikaterini Fotopoulou4, Dimitrios Kipreos1,

Stamatina Patsavela1, Argiro Loukou1, Athanasios Bazinis5,

Dimitra Daskalopoulou6, Emmanouil Paraskevas1

1Gastroenterology, 2CT Dpt., Agios Savvas Cancer Hospital, Athens,

3Nuclear Medicine, University of Thrace, Alexandroupolis,

4Radiation Oncology, 5Psychiatry, 6Cytology, Agios Savvas Cancer

Hospital, Athens, Greece

17:30 -17:45 • O-021 A phase II study of sunitinib in patients with advanced

hepatocellular carcinoma

Authors: Andrew Zhu*1,Dusyhant V. Sahani1, Emmanuelle di

Tomaso1, Dan Duda1, Vivek Sindhwani1, Sam S. Yoon1, Lawrence S.

Blaszkowsky1, Jeffrey W. Clark1, David P. Ryan1, Rakesh K. Jain1

17.00 - 18.30 General Session 4: Clinical trials and treatment (RCTs and new therapies)

Saturday, 6 October


1Cancer Center, Massachusetts General Hospital Cancer Center,

Boston, United States

17.45- 18.00 • O-022 Sorafenib improves survival in hepatocellular carcinoma:

results of a phase III randomized placebo-controlled trial

Authors: Jordi Bruix*1,Sergio Ricci2, Vincenzo Mazzaferro3, Philip

Hilgard4, Jean-Luc Raoul5, Armando Santoro6, Jean-Frédéric Blanc7,

Edward Gane8, Stefan Zeuzem9, Minghua Shan10,

Marius Moscovici11, Dimitris Voliotis12, Josep M. Llovet13

1Unidad de cancer hepático, Hospital Clinic i Procincial, Barcelona,

Spain, 2Unità Operativa di Oncologia Medica, Azienda Ospedaliera

Universitaria Pisana, Pisa, 3Unità Operativa Chirurgia Apparato

Digerente e Trapianto di Fegato, IRCCS, Milano, Italy, 4Dept. for

Gastroenterology und Hepatology, University Hospital Essen, Essen,

Germany, 5Département d'Oncologie Médicale, Centre Eugène

Marquis, RENNES, France, 6Dipartimento Oncologia Medica e

Ematologia, Istituto Clinico Humanitas, Rozzano, Italy, 7Service

d'hépato-gastroentérologie, Hôpital Saint André, BORDEAUX,

France, 8NZ Liver Transplant Unit, Auckland City Hospital, Auckland,

New Zealand, 9Abteilung für Innere Medizin, Universitätsklinikum

des Saarlandes, Homburg, Germany, 10Bayer, Pharmaceuticals,

West Haven, United States, 11Bayer, Pharmaceuticals, Viale

Certosa, Italy, 12Bayer, Pharmaceuticals, Wuppertal, Germany,

13Division of Liver Diseases, Mount Sinai School of Medicine,

New York, United States

18.00 - 18.15 • O-023 A randomized trial comparing 3-month vs. 6-month screening

for HCC by ultrasonography in cirrhosis

Authors: Michel Beaugrand*1,Jean Claude Trinchet1,

Cooperative group GRETCH1

1Hepatology, Jean Verdier hospital, Bondy, France

18.15 - 18.30 • O-024 Four decades’ studies on hepatocellular carcinoma – from

bench to bedside

Author: Zhao-You Tang*1

1Liver Surgery, Liver Cancer Institute and Zhongshan Hospital,

Fudan University, Shanghai, China

General Sessions


Symposia

Industry Symposia

Other MeetingsSaturday, 6 October


Sunday, 7 October Room

Lleida/Tarragona

Chair: H. El-Serag (USA)

Presenter: P.Hainaut (France)

Lleida/Tarragona

Chairs: Peter Galle, Mainz (Germany), Kazuhiko Koike, Tokyo (Japan)

• Signaling pathways in the pathogenesis of HBV and HCV-related HCC

Jack R. Wands, Providence (USA)

• Telomere shortening, cirrhosis, and cancer

Lenhard Rudolph, Hannover (Germany)

• The wnt canonical pathway in benign and malignant liver tumors

Jessica Zucman-Rossi, Paris (France)

• Linking signaling pathways and clinical outcomes in liver cancer

Snorri Thorgeirsson, Bethesda (USA)

Lleida/TarragonaChair: Vincenzo Mazzaferro, Milan (Italy)Speaker: Masatoshi Makuuchi, Tokyo (Japan)

Lleida/TarragonaChairs: M. Sherman (Canada), K. Takayasu (Japan)

12.30 - 12.45 • O-025 Outcome and prognostic factors of untreated hepatocellular

carcinoma (HCC) on cirrhosis

Authors: Luisa Benvegnu*1,Maurizio Gios1, Francesca Pasin1, Annamaria Di Nolfo2,

Paolo Del Poggio3, Gianludovico Rapaccini4, Fabio Farinati5, Marco Zoli6, Franco Borzio7,

Edoardo G. Giannini8, Eugenio Caturelli9, Alfredo Alberti1, Mauro Bernardi10,

Franco Trevisani10

1Dpt. of Clinical and Experimental Medicine, University of Padova, Padova, 2Dpt. Medicine,

Hospital, Seriate, 3Dpt. Medicine, Hospital, Treviglio, 4Internal Medicine, University of

Roma, Roma, 5Dpt. Surgical and Gastroenterological Science, University of Padova,

Padova, 6Dpt. Internal Medicine, University of Bologna, Bologna, 7Dpt. Medicine, Hospital,

Milano,8Dpt. Internal Medicine, University of Genova, Genova, 9Dpt. of Gastroenterology,

Belcolle Hospital, Viterbo, 10Dpt. of Gastroenterology, University of Bologna, Bologna, Italy

12.30 - 14.00 General Session 5: Diagnosis, staging and prognosis

11.30 - 12.30 The Clinical Lecture: Past, present and future of surgical management of HCC

IARC's research agenda for combating liver cancer worldwide08.30 - 09.00

Symposium: Signal transduction pathways in liver tumors09.00 - 11.00

Sunday, 7 October


12.45 - 13.00 • O-026 Detection of hypervascular foci in hypovascular borderline lesion

upon cirrhotic liver: comparison of dynamic contrast enhanced

multi-detector row CT, dynamic gadolinium-enhanced MR, and

SPIO-enhanced MR imaging

Authors: Satoshi Kobayashi*1,Rieko Shinmura1, Osamu Matsui1,

Toshifumi Gabata1, Junichiro Sanada1, Wataru Koda1, Tetsuya Minami1,

Yasuji Ryu1

1Radiology, Kanazawa University School of Medicine, Kanazawa, Japan

13.00 -13.15 • O-027 Vessel invasion of hepatocellular carcinoma: can high risk

factors be identified on preoperative CT scan?

Author: Mi-Suk Park*1

1Department of Diagnostic Radiology, Severance Hospital, Yonsei University

College of Medicine, Seoul, South Korea

13.15 -13.30 • O-028 Clinicopathological study on cholangiolocellular carcinomasuggesting hepatic progenitor cell origin Authors: Mina Komuta*1, Sara Vander Borght1, Raymond Aerts2,Masamichi Kojiro3, Tania Roskams1

1Pathology, K.U Leuven, 2Abdominal Surgery Section, KU Leuven University Hospitals

of Gasthuisberg, Leuven, Belgium, 3Pathology, Kurume University, Kurume, Japan

13.30 - 13.45 • O-029 Sequencing of HVRII and HVRIII of mitochondrial-DNA distincts

between disseminated and synchronic hepatocellular carcinoma

(HCC)

Authors: Maria Varela*1, Loreto Boix1, Manel Sole2, Alejandro Forner1,

Amelia J. Hessheimer1, Jordi Bruix1

1BCLC group. Liver Unit, 2Pathology Department., Hospital Clinic, Barcelona, Spain

13.45 -14.00 • O-030 Loss of heterozygosity at D8S298 is a predictor for long-term

survival of patients with TNM stage I of hepatocellular carcinoma

Authors: Lun-Xiu Qin*1, Jin-Zhong Pang1, Ning Ren1, Qing-Hai Ye1, Yin-Kun Liu1,

Zhao-You Tang1

1Dept of Liver Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China

Lleida/TarragonaClosing Remarks14.00 - 14.10

Sunday, 7 October

General Sessions


Symposia

Industry Symposia

Other Meetings


TOP SCORED POSTERS5 – 6 October 2007

1. Molecular pathogenesis, cell biology and translational researchP-001 Gene expression profiles reveal common features between reversal of

hepatocellular malignancy and cellular senescence P-002 Vaccination with dendritic cells transduced with a CD40L-expressing adenovirus

and an AFP-encoding adenovirus induces specific inhibition of subcutaneous hepatocellular tumor growth in mice

P-003 Accelerated orthotopic HCC growth is linked with increased pro-angiogenic and pro-lymphangiogenic factors in liver fibrosis

P-004 Transarterial chemoembolization of unresectable hepatocellular carcinoma (HCC) with drug eluting beads (DEB); results of an open label study of 62 patients

P-005 Liver transplantation as rescue therapy for intrahepatic recurrence of hepatocellular carcinoma in non-cirrhotic livers after partial liver resection

P-006 Expression and function of Wilms’ tumour suppressor (WT1) gene in human hepatocellular carcinoma

P-007 Gene expression profiling in hepatocellular carcinoma and adenoma: upregulation of genes in amplified chromosome regions

P-008 The HDM-2/P53 pathway is regulated by iron status in hepatocytes and human primary monocytes, and HDM-2 genotype affects hepatocellular carcinoma risk during iron overload

P-009 Expression of MRP1 in HCC is associated with a more aggressive tumour phenotype and can reflect a progenitor cell origin

P-010 Evolving cytogenetic anomalies in long-term cultures of telomerase-immortalizedhuman fetal hepatocytes

P-011 Ras/PI3-K/Akt promotes cellular growth by enhancing alternative splicing-mediated inactivation of the KLF6 tumour suppressor in human hepatocellular carcinoma

3. Diagnostic imaging and molecular pathologyP-012 Diagnosis of hepatocellular carcinoma (HCC) < 20 mm detected during

surveillance in cirrhosis. Diagnostic value of dynamic imaging techniques P-013 Toronto hepatocellular carcinoma screening protocol (THSP): Initial North American

experience with systematic implementation of American association for study of liver disease (AASLD) heptoma screening and workup guidelines

P-014 thorough assessment of portal venous thrombosis in patients with hcc allows adequate selection of candidates for liver transplantation

P-015 MDM2 promoter SNP 309 is associated with the presence and earlier onset of hepatocellular carcinoma

5. MiscellaneousP-016 Hepatocyte differentiation in cholangiocarcinoma, suggesting hepatic progenitor

cell origin P-017 Octreotide differentially modifies TNFR1, TNFR2 and TNF\alpha in rat Kupffer cells.

Possible implications for its antineoplastic effect in hepatocellular carcinoma

POSTERSFriday, 5 October 2007

1. Molecular pathogenesis, cell biology and translational researchP-018 MDM2 SNP309 G allele and p53 mutations are mutually exclusive in human

hepatocellular carcinomas P-019 Life/death decisions governed by epithelial cell polarity: the case of Fas signalling

in hepatocytes P-020 Low occurrence of occult HBV in patients with cirrhosis due to HCV with

or without HCC P-021 HCV and ethanol induce mitosis dysregulation via different intracellular pathways P-022 Risk of resection of hepatocellular carcinoma in patients with a metabolic syndrome P-023 significance of the anti-inflammatory factor hemeoxgenase-1 (HO-1) for the

function of tumour infiltrating macrophages in human hepatocellular carcinoma P-024 Control of hepatocytes adhesion and migration by TGF-beta P-025 Lanreotide inhibits pre-neoplastic and neoplastic nodules induction by interfering

with the proliferation/apoptosis balance in a rat model of liver carcinogenesis P-026 Analysis of Glypican 3-specific CD4+ T cell responses in hepatocellular

carcinoma patients P-027 Prostaglandin E2-receptor (EP1-4) antagonism as a novel approach to the

treatment of hepatocellular carcinoma (HCC) P-028 Newly identified hepatic progenitor cell (oval cell) proliferation and mitochondrial

abnormalities are characteristic of the hepatocellular carcinoma and liver injury associated with alpha-1-antitrypsin deficiency in human liver and mouse models

P-029 Biological significance of the marker DCP or PIVKA-2 P-030 Candidate HCC biomarkers identified by HepG2 microarray P-031 Candidate biomarkers of cirrhosis and HCC identified by serum proteomics in

patients with NAFLD P-032 Role of c-Met in regulation of liver progenitor cell survival P-033 High-resolution single-nucleotide polymorphism array analysis in human

hepatocellular cancer (HCC) cell lines reveal new candidate genes P-034 Clinicopathological features and predictive factors of survival after complete

surgical resection for fibrolamellar hepatocellular carcinoma P-035 The frizzled module of collagen 18 inhibits the Wnt/b-catenin signalling in human

hepatocellular carcinomas P-036 MboII and NlaIV gene polymorphisms of human MDM2 gene in patients with

hepatocellular carcinoma P-037 Inhibition of the MAPK/ERK pathway potentiates TGF-beta-induced apoptosis in

HepG2 cells: role of oxidative stress P-038 Recruitment of genetically engineered endothelial progenitor cells by lentiviral

vectors in experimental models with hepatocellular carcinoma P-039 EGR-1 is induced by growth factors in PHH and HCC cells in a

MEK/ERK-dependent manner P-040 VX2 liver tumour response to intra-arterial infusion of 3-bromopyruvate:

sequential assessment by FDG PET/CT imaging P-041 Laminin-5 stimulates hepatocellular carcinoma growth through a different

function of alpha6beta4 and alpha3beta1 integrins P-042 Significance of fibroblast growth factors (FGF) 8, 17, and 18

for hepatocarcinogenesis

Posters

A poster exhibition will take place during the conference. Posters will be on display all day long from 09.00 to 18.00 on Friday, 5 October and Saturday, 6 October in the Sitges, Rosas and Girona rooms of the Gran Hotel Princesa Sofia, venue of the conference.

Posters will be displayed for one day, according to their topic.Top scored posters will be displayed on both days: Friday, 5 October and Saturday, 6 October.

FRIDAY, 5 OCTOBER Topic 1: Molecular pathogenesis, cell biology, and translational research

SATURDAY, 6 OCTOBER Topic 2: Epidemiology, staging and prognosisTopic 3: Diagnostic imaging and molecular pathologyTopic 4: Clinical trials and treatment researchTopic 5: Miscellaneous


P-043 Evidence for NORE1B to act as tumor suppressor gene in human hepatocellular carcinoma

P-044 New epithelial and mesenchymal cell lines from hepatocellular carcinoma to study cell interactions

P-045 Myeloid derived suppressor cells impair tumour specific immune responses in HCC P-046 Intra-tumoral myeloid dendritic cells in HCC patients are monocytic and hamper

tumour specific immune responses P-047 on the basis of its expression in primary hepatocellular carcinoma, sperm

protein 17 is a potential immunotherapeutic target P-048 Expression of HLA class I and antigen-processing and presenting machinery

molecules in primary hepatocellular carcinoma P-049 IFN-alpha-induced trail-mediated apoptosis in hepatoma cells requires

functional PML and P53 P-050 Prevalence of "occult" hepatitis B virus infection in Southern African blacks with

hepatocellular carcinoma P-051 Bax inhibitor-1 mRna expression in chronic hepatitis, cirrhosis, and hepatocellular

carcinoma P-052 Targeting SIRT1 for anti-tumour therapy: inhibition of SIRT1 down-regulates

HIF-1alpha P-053 Angiogenesis soluble factors as HCC non-invasive markers for monitoring HCV

cirrhotic patients awaiting liver transplantation P-054 Genes involved in carcinogenesis in hepatitis C-hepatocellular carcinoma (HCC)

progression P-055 Detection of Prox1-positive progenitor cells in liver cirrhosis and hepatocellular

carcinoma P-056 Effects of HINT2, a putative tumour suppressor, on mitochondrial functions P-057 Enhanced cell killing in human hepatoma cells with different p53 status by

parvovirus H1 with chemotherapeutic agents P-058 Pathologic study on combined hepatocellular and cholangiocellular carcinoma

with a reference to its histogenesis P-059 Activation of the Wnt/b-catenin pathway in hepatocellular carcinoma, and in vitro

growth inhibition with novel small molecule ICG-001 P-060 Epigenetic gene expression profiling identified tissue-factor pathway inhibitor-2, TFPI-2,

as a frequently silenced candidate tumour suppressor gene in human HCC P-061 HCV core protein induces cytokine secretion and proliferation in TLR2 positive

hepatoma cells P-062 Low serum apolipotrein A1 is predictive of HCC development in patients with

viral C cirrhosis P-063 B allele group is associated with a decrease risk of HCC occurrence in patients

with viral C and alcoholic cirrhosis P-064 Beta- blockers decrease occurrence of HCC in patients with viral C cirrhosis

and oesophageal varices P-065 Genome-wide molecular profiles of HCV-induced hepatocellular carcinoma P-066 Mass forming type of intrahepatic cholangiocellular carcinoma: favouring factors

and histological changes in the non tumourous liver P-067 Codon 249 mutation in TP53 is frequently found in poorly differentiated

hepatocellular carcinoma in Brazil 33P-068 Kupffer cells as essential players in innate immune response for partial

hepatectomy and laporotomy P-069 Inhibition of mTOR in combination with doxorubicin in an experimental model

of hepatocellular carcinoma P-070 Inhibition of hepatic tumour angiogenesis with met inhibitors P-071 Characterization of stem cell lineages in the liver of patients with hepatic tumours P-072 Posttranscriptional VEGF inhibition reduces tumour growth in an experimental

murine HCC model P-073 Influence of angiostatin K1-3 on the metastatic potential of murine HCC cells

in vitro and in vivo P-074 The density of oval-shaped progenitor-like cells in liver cirrhosis is related to HCC

development P-075 NFkB-subunit expression in hepatocytes and immunocytes in cirrhosis and HCC P-076 Not-proliferating, committed to proliferate and proliferating hepatocytes in human

hepatocarcinogenesis P-077 overexpression, role and post-transcriptional regulation of pontin in human

hepatocellular carcinoma (HCC) P-078 Proteomics suggests acute enflammation as a key for initiation and early

promotion of rat liver cancer P-079 The p53 family network regulates induction of apoptosis and chemosensitivity

in hepatocellular carcinoma P-080 Circulating vascular endothelial growth factor (VEGF) and related cytokines in

unresectable hepatocellular carcinoma (HCC) P-081 TGF-beta induces p53/RB-independent, but oxidative stress-dependent cellular

senescence in hepatocellular carcinoma cells

P-082 Metabolic profiling of bile: diagnostic potential of magnetic resonace spectroscopy P-083 Hepatitis C virus modulates hepatocyte apoptosis by targeting Bid P-084 Protumorigenic overexpression of stathmin/op18 by gain of function mutation in

p53 in human hepatocarcinogenesis P-085 Chromatinic losses associated to liver fibrosis samples from chronic hepatitis C

virus patients P-086 Expression of c-MYC protein on the progression of hepatitis C virus associated

liver fibrosis P-087 Intrahepatic accumulation of AFP-specific T cell responses in patients with HCC

with and without HCV infectionP-088 Emodin avoids the rearrangement of adhesion molecules induced by HCV P-089 Keratin 19 positive hepatocellular carcinomas express various hepatic progenitor

cell markers P-090 A phase II study of bevacizumab, capecitabine and oxalipatin combinnation in the

treatment of advanced/metastatic hepatocellular carcinoma P-091 Angiogenic switch as a molecular target of hepatocellular carcinoma P-093 Neovascularization correlates with lymph node metastases and prognosis in hilar

cholangiocarcinoma P-094 Liver specific overexpression of PDGF-B promotes tumour development in a model

of chemically induced liver carcinogenesis P-095 Increased tumour incidence in MMP-9-transgenic mice in a model of liver

carcinogenesis P-096 Role of insulin-like growth factor signaling pathway in hepatocellular carcinoma.

Molecular targeted therapies blocking IGF pathway P-097 Proteomics analysis reveals overexpression of prohibitin in cultured cell and

mouse expressing hepatitis C virus core protein P-098 Incidence of mixed hepatocellular and cholangiocarcinoma from 1991 to 2006

in the Ghent University Hospital P-099 Chemotherapy-induced hypoxia contributes to the up-regulation of breast

cancer resistance protein expression in hepatoblastoma P-100 Squamous cell carcinoma antigen (SCCA) enhances liver regeneration after

partial hepatectomy P-101 Proteomics approach to early hepatocellular carcinoma biomarker discovery P-102 mTOR inhibition enhances chemo-cytotoxicity in hepatocellular carcinoma

through both p53 dependent and independent pathways P-103 Novel monoclonal antibodies with selective affinity for cytosolic/nuclear forms

of beta-catenin protein P-104 Implications of mutant p53 gain of function in hepatocellular carcinoma studied

by microarray analysis P-105 Analysing protein-protein interaction networks of human liver cancer cell lines

with diverse metastasis potential P-271 A hepatotropic peptide to improve the efficacy of anti-tumour agents in

patients with HCC

POSTERSSaturday, 6 October 2007

2. Epidemiology, staging and prognosisP-106 Etiology of hepatocellular carcinoma (HCC) in elderly patients with non significant

fibrosis treated surgically P-107 Outcome in elderly patients treated surgically for hepatocellular carcinoma (HCC) P-108 Mortality in patients with hepatocellular carcinoma (HCC) predicted by six scoring

systems P-109 Hepatitis C (HCV) recurrence in patients transplanted for HCV-related cirrhosis

with HCC P-110 Prognosis of cirrhotic patients with well-preserved liver function and hepatocellular

carcinoma within Milan criteria P-111 Quantitative analysis of angiogenesis, proliferative activity, DNA aneuploidy and P53

expression: relation with hepatocellular carcinoma recurrence and prognosis P-112 Early and very early HCC. When and how much does the treatment choice matter? P-113 Multimodality treatment and prognostic factors for survival in 169 patients with

unresectable hepatocellular carcinoma: a five-year single-center experience P-114 Meld and HCC: impact on 3-year survival following liver transplantation (LT) P-115 Prognostic factors for predicting survival in the interventional radiology therapies

of hepatocellular carcinoma P-116 Role of primary resection for HCC under the era of liver transplantation P-117 A 10-year retrospective analysis of risk factors, patterns of cancer recurrence,

and survival post liver transplant for cirrhosis and hepatocellular carcinoma P-118 Impact of tumor size and vascular invasion on survival of patients with small

hepatocellular carcinoma P-119 Hepatocellular carcinoma (HCC) in biopsy proven nonalcoholic steatohepatitis (NASH) P-120 Postoperative tumor staging based on histological findings is crucial to predict

prognosis of hepatocellar carcinoma


P-121 Incidence and risk factors of the hepatocellular carcinoma in the south of Madrid community (Central Spain). A case-control study

P-122 External validation of a new prognostic score predicting recurrence of hepatocellular carcinoma after liver transplantation

P-123 Prognosis of patients with cholangiocarcinoma in an american cohort P-124 Chemoembolization of hepatocellular carcinoma: is etiology of cirrhosis an

independant prognostic factor of survival?

P-121 Incidence and risk factors of the hepatocellular carcinoma in the south of Madrid community (Central Spain). A case-control study

P-122 External validation of a new prognostic score predicting recurrence of hepatocellular carcinoma after liver transplantation

P-123 Prognosis of patients with cholangiocarcinoma in an american cohort P-124 Chemoembolization of hepatocellular carcinoma: is etiology of cirrhosis an

independant prognostic factor of survival? P-125 Liver iron, HFE gene mutations and hepatocellular carcinoma occurrence in

patients with cirrhosisP-126 Pre-transplant ablation is associated with improved post-transplant survival in

HCC patients exceeding unos/Milan criteria P-127 Liver tumors in patients with Fanconi anemia P-128 Hilar and peripheralcholangiocarcinomas (CCC) share similar clinico-biological

characteristics P-129 Identification of MSRA gene on chromosome 8P as a candidate metastasis

suppressor for human hepatitis B virus-positive hepatocellular carcinoma P-130 Prospective evaluation of staging systems for hepatocellular carcinoma detected

during surveillance of cirrhotic patients P-131 HIV-infected patients with hepatocellular carcinoma have decreased survival

than non-HIV patients adjusted by BCLC class P-132 Hepatocellular carcinoma in patients with autoimmune hepatitis P-133 Squamous cell carcinoma antigen-1 (SCCA1) polymorphism and liver disease

stage in chronic HCV infection P-134 8 years surveillance program for hepatocellular carcinoma in cirrhotic patients

in São Paulo, BrazilP-135 Hepatitis B past infection and HCV related HCC

3. Diagnostic imaging and molecular pathology P-136 Clinicopahological and gene expression profiles of macrovascular versus

microvascular invasion of hepatocellular carcinoma P-137 Individual and regional liver sensitivity to radiation assessed by CT portal venous

perfusion imaging P-139 Catheter-directed dosimetry as an adjunct to SIRT P-140 Evaluation of tumour response after locoregional therapies in hepatocellular

carcinoma (HCC): are recist criteria reliable? P-141 Impact of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET)

on outcome and chemo-sensitivity in hepatocellular carcinoma patients P-142 Accuracy of MR Imaging for the detection of hepatocellular carcinoma in patients

with cirrhosis: correlation with the whole explanted liver P-143 Enhancement patterns of hepatocellular carcinoma on contrast-enhanced

ultrasound: comparison with histologic differentiation P-144 Changes in enhancement and morphology on CT imaging in hepatocellular

carcinoma treated with Bevacizumab and Erlotinib P-145 Toronto hepatocellular carcinoma screening protocol (THSP): analysis of 3 modality

approach to workup of small or indeterminate lesions detected at screening for HCC P-146 Delayed hypointensity of arterially-enhancing nodules in cirrhotic livers for

diagnosis of hepatocellular carcinoma P-147 Irregular regeneration is a diffuse finding possibly related to hepatocellular

carcinoma in hepatitis C cirrhosis P-148 Small nodules (10-20 mm) in liver cirrhosis: characterization with

contrast-enhanced ultrasound P-149 Haemodynamic analysis of small hepatic lymphoid tumours with angiography

assisted CT P-150 Imaging of benign hypervascular hepatocellular nodules in alcoholic liver cirrhosis:

differentiation from hypervascular hepatocellular carcinoma P-151 Hepato-cellular carcinoma-induced in familial non-alcoholic steatohepatitis P-152 Somatostatin receptors (SSTR) screening in hepatocellular carcinoma (HCC):

comparison between Octreoscan® and Neospect®: a pilot studyP-153 6D5 monoclonal antibody as a promising tissue marker of hepatocellular carcinoma P-154 Is the radiologic stage according with the patologic stage in liver transplantation? P-155 Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular

carcinoma in cirrhotic patients

4. Clinical trials and treatment researchP-156 Treatment of hepatocellular carcioma by radiofrequency thermal ablation versus

transcatherter hepatic arterial chemoembolization with or without subcutanous viscum (Fraxini (2))injection

P-157 A3 adenosine receptor expression and functionality in hepatocellular carcinoma: involvement of nf-kappa b

P-158 Epidemiology and outcome of hepatocellular carcinoma in Lombardy. A population-based study

P-159 Chemotherapy could be a therapeutic option for hepatocellular carcinoma (HCC in patients with non cirrhotic liver

P-160 Adjuvant intra-arterial injection of iodine-131-labeled lipidol after resection of hepatocellular carcinoma: progress report of a case – control study with a 5 years minimal follow-up

P-161 Preliminary results of "metronomic" capecitabine treatment in advanced hepatocellular carcinoma (HCC)

P-162 Preliminary results of "metronomic" capecitabine treatment in advanced epatocellular carcinoma (HCC)

P-163 Phase I/II trial of continuous hepatic arterial infusion (HAI) of irinotecan in patients with hepatocellular carcinoma (HCC)

P-164 Three radiofrequency systems for non-small hepatocellular carcinoma: comparative technique effectiveness after one session

P-165 Tace of HCC with occlusin®50 and doxorubicin: phase I results of a new embolic agent

P-166 Hepatoblastoma in patients aged 10-18 years. Report from the international childhood liver tumor strategy group (SIOPEL)

P-167 Arterial chemoembolization pre-liver transplantation in HCC. Is it useful? P-168 Recurrence of hepatocellular carcinoma after liver transplantation P-169 Liver transplantation after laparoscopic liver resection for hepatocellular carcinoma P-170 What is the best staging system to predict the survival after curative resection

for hepatocellular carcinoma? P-171 Single-agent pemetrexed does not appear to benefit patients with advanced

hepatoma in the community setting P-172 Phase II study of amplitude-modulated electromagnetic fields in the treatment

of advanced hepatocellular carcinoma P-173 Liver transplantation for hepatocellular carcinoma: validation of a new prognostic

score predicting disease-free survival P-174 Moderate expansion of milan criteria for transplantation for HCC does not impact

survival nor recurrence rates P-175 Thymostimulin in advanced hepatocellular carcinoma: a phase II trial P-176 Time-to-progression as a parameter for evaluating the therapeutic effects

of transcatheter arterial chemoembolization in patients with advanced hepatocellular carcinoma

P-177 Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma P-178 Gemcitabine-based transcatheter arterial chemoembolization (TACE) for

unresectable cholangiocarcinoma P-179 Right hepatic lobectomy using the staple technique in 101 patients P-180 LY2109761 as a potential drug for HCC. A preclinical studyP-181 Liver transplantation for hepatocellular carcinoma: a new policy on selection

criteria and organ allocation P-183 Re-evaluation of the Milan criteria for liver transplantation in patients with

hepatocellular carcinoma P-184 Transarterial chemoembolization (TACE) for inoperable intrahepatic

cholangiocarcinoma P-185 Liver transplantation in hepatocellular carcinoma across Milan criteria P-186 Phase I and pharmacokinetic study of S-1 for advanced hepatocellular carcinoma:

impact of liver disorder P-187 Prospective study on hepatocellular carcinoma. epidemiological, clinical

characteristics and results of treatement P-188 Phase I/II study to assess the safety/tolerability/pharmacokinetics of MB07133

in subjects with unresectable hepatocellular carcinoma P-189 Radioembolization of advanced hepatocellular carcinoma using 90y-resin

microspheres results in significant control of local tumor growth P-190 Efficacy of interventional radiology therapies in hepatocellular carcinoma

assessed by local response and survival P-191 The effect of hepatic arterial infusion therapy for PVT in the advanced HCC P-192 Stabilization of disease after repeated intrahepatic infusion of oncolytic herpes

simplex virus NV1020 prior to 2nd-line chemotherapy with CPT-11 + and cetuximab in a patient with progressive colorectal cancer metastatic to the liver

P-193 Phase II study of 4-fraction carbon ion radiotherapy for hepatocellular carcinoma P-194 Efficacy of hepatic resection after preoperative combined transarterial chemotherapy

and radiation therapy in hepatocellular carcinoma more than 5 cm in size

Posters


P-195 Was combination therapy superior to mono-therapy in localized hepatocellular carcinoma with portal vein thrombosis?

P-196 Seeding after radiofrequency thermal ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study

P-197 Doxorubicin eluting beads-enhanced radiofrequency ablation of hepatocellular carcinoma

P-198 The aspects of the immune circulating cells in chronic hepatitis C with heavy alcohol intake and hepatic neopasia

P-199 Prolonged expression of interleukin-12 is required for sustained antitumor effect in a murine model of liver metastases

P-200 Efficacy of high-dose conformal radiotherapy (CRT) plus transarterial chemoembolization (TACE) for locally advanced hepatocellular carcinoma (HCC)

P-201 Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial

P-203 Evaluation for the candidates of living donor liver transplantation for hepatocellular carcinoma

P-204 Liver segmental volume changes in patients with intrahepatic malignancies treated with focal liver radiation therapy

P-205 Intrahepatic tumor perfusion as measured by dynamic contrast enhanced ct may be predictive of tumor response

P-206 Percutaneous treatment of small hepatocellular carcinoma: ethanol injection or radiofrequency ablation? Clinical experience of a single centre

P-207 Percutaneous radio-frequency ablation of small HCC: factors related to clinical outcome and recurrence of disease

P-208 Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma

P-209 Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma

P-210 Results of resection and transplantation for HCC in cirrhosis and non- cirrhosis P-211 Radiofrequency ablation for the treatment of small recurrent hepatocellular

carcinoma: control study comparing with surgical resection P-212 Relationship of pulmonary shunt fraction to survival in patients with

hepatocellular carcinoma being considered for Y90 radioembolization P-213 Prognostic factors in patients with hepatocellular carcinoma and macroscopic

vascular invasionP-214 Dual induction of PKR with E2F1 and interferon alpha to enhance gene therapy

against hepatocellular carcinoma P-215 Chemoembolisation (TACE) with doxorubicin and lipiodol alone for extensive

hepatocelullar carcinoma P-216 Therapeutic outcomes of radiofrequency ablation under general anesthesia for

hepatocellular carcinoma: surgery versus RFA P-217 Treatment of unresectable hepatocellular carcinoma using transarterial Y90

radiotherapy: long-term survival and stratification analysis P-218 Pattern of care study on radiotherapy for locally advanced hepatocellular

carcinoma (HCC) P-219 Efficacy and tolerance of multipolar radiofrequency ablation for the treatment of

large HCC larger than 5 cm P-220 Left lobe location of hepatocellular carcinoma as a risk factor of complications

of radiofrequency ablation P-221 Therapy of patients with advanced hepatocellular carcinoma with octreotide P-223 Study of some associated factors with hepatocellular carcinoma in Egypt P-224 Discovery of the missed link between schistosomiasis and hcv infection P-225 Combined chemoembolization and percutaneous radiofrequency ablation for

local control of liver tumors P-226 CAM/Ethiodol/PVA chemoembolization of intrahepatic cholangiocarcinoma P-227 Clinically significant hepatic artery injury following tace: fact or fiction P-228 Recurrence and outcomes after local therapy for the treatment of small

hepatocellular carcinoma: experience at a single center P-229 Recurrence and outcomes after local therapy for the treatment of small

hepatocellular carcinoma: experience at a single center P-230 Transarterial lipiodol infusion chemotherapy for 2,523 patients with unresectable

hepatocellular carcinoma studied by the liver cancer study group of Japan P-231 Reconsidering the therapeutic output of the barcelona-clinic-liver-classification:

a new role for surgery P-232 Impact of the use of living donors and prioritization by meld score on the

applicability of liver transplantation for hepatocellular carcinoma P-233 Molecular combined therapy in hepatocellular carcinoma with AEE788

(EGFR/HER2/VEGFR inhibitor) and RAD001, everolimus (MTOR inhibitor) P-235 Long-term immunomodulatory side effects of RFA in patients with liver

metastases of colorectal cancer and HCC

P-236 Migration and expansion of dendritic cells induce a strong antitumor immune response in virotherapy which provide an inflammatory environment for effective DC vaccination

P-237 Clinicopathological significance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) in patients with hepatocelular carcinoma (HCC)

P-238 Do patients with hepatocellular carcinoma and hepatitis C have worse or better outcome after liver transplantation than patients with hepatitis C alone?

P-239 Induction of immunosuppressive molecules counteract the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer

P-270 Child’s A patients with small hepatocellular carcinoma within Milan criteria: resection or transplant?

5. MiscellaneousP-240 Differential expression of Slit-Robo genes in cells derived from hepatocellular

carcinoma P-241 Possible regression of Danazol induced-hepatocellular tumours after

stopping treatment P-242 The proteasome inhibitor Bortezomib and oncolytic virotherapy act

synergistically in hepatocellular carcinoma P-243 A quantitative proteomic approach for identification of biomarkers in

hepatocellular carcinoma P-244 Laparoscopic liver resection for hepatocellular carcinoma (HCC) complicating

chronic liver disease P-245 Validation study of the prognostic immunohistochemical marker glypican-3

in hepatocellular carcinoma P-246 Blood telomerase activity and DNA dielectric properties in human hepatocellular

carcinoma and chronic liver disease P-247 Laparoscopic cholecystectomy in the cirrhotic patient P-248 The conditionally replicating adenovirus adsensor-p53t for the treatment of tumours

harboring activated telomerase and aberrations in p53-transcriptional activity P-249 MR Imaging for the assessment of treatment response after radiofrequency

ablation of hepatocellular carcinoma: an explant correlation P-250 Can liver stiffness measurements predict the presence of hepatocellular

carcinoma in patients with hepatitis b-virus related liver disease? P-251 Mortality and predictive tumour criteria for survival after OLT in patients with

primary liver malignancy (HCC) P-252 The oncolytic adenovirus adp53-sensor replicates selectively in p53-altered

tumour cells and potential tumour spectrum is not limited by the p73 status P-253 Dosimetric comparison of 3d-conformal radiotherapy, intensity modulated

radiotherapy, and helical tomotherapy for hepatocellular carcinoma P-254 Drop-out rates in patients with hepatocellular carcinoma within Milan’s criteria

waiting for liver transplantation P-255 The impact of small-for-size syndrome on tumour recurrence after LDLT for HCCP-256 Phase 2 validation study comparing des-gamma carboxyprothrombin (DCP),

total alpha-fetoprotein (AFP) and AFP-L3 P-257 Tumour recurrence following liver transplantation for hepatocellular carcinoma:

role of tumour proliferation status P-258 Liver stiffness measurement in patients with cirrhosis and hepatocellular

carcinoma: a case-control study P-259 Cortistatin, proinflammatory cytokines, ethanol and acetaldehyde as possible

mechanisms of hepatocellular carcinoma resistance to octreotide P-260 Telomerase-dependent conditionally replicating adenovirus expressing

CARex-PTDs displays enhanced oncolytic properties in CAR-deficient tumours P-261 Increased age does not imply in higher HCC patients mortality in a referral

tertiary hospital P-262 Immediate cytological diagnosis of primary malignant liver tumours P-263 SULF2 - A novel oncogenic protein in hepatocellular carcinoma (HCC) P-264 Proteomic identification in plasma of new molecular markers for hepatocellular

carcinoma P-265 Differential expression of hepatitis B virus x antigen in tumour and adjacent

nontumour hepatocytes in hepatitis B related hepatocellular carcinoma P-266 The development of a swine model of secondary liver tumours from a

genetically induced swine fibroblasts cell line P-267 The relation ship between indocyanine green test and portal venous pressure P-268 Cui malo? a decision analysis of expanding Milan criteria for liver transplantation

of hepatocellular carcinoma P-269 The hepatoblastoma tumour family : a novel concept based on the SIOPEL

experience


Friday, 5 October Room

Lleida/Tarragona

Chair: Jordi Bruix, Barcelona (Spain)

• The scientific rationale for TACE and health/safety considerations

Irene Krämer, Mainz (Germany)

• An overview of the clinical data


• Device selection and delivery technique

Riccardo Lencioni, Pisa (Italy)

• Oncology perspectives on the management of liver cancer

Michel Ducreux, Villejuif (France)

Lunch will be provided prior to the Biocompatibles symposium.

Lleida/Tarragona

Chair: Jordi Bruix, Barcelona (Spain)

• Welcome and introduction


• Hepatocellular carcinoma: current approaches to management


• Targeting the underlying molecular mechanisms of hepatocellular

carcinoma

Gregory J. Gores, Rochester (USA)

• Management of hepatocellular carcinoma: recent advances and

future prospects


• Discussion and concluding remarks

Refreshments will be provided.

18.00 - 19.30 Industry Symposium (Bayer Schering Pharma)Recent advances with targeted therapies: a new era in the management of hepatocellular carcinoma

11.30 - 13.15 Industry Symposium (Biocompatibles)

TACE in HCC: A multi-disciplinary overview

Industry Symposia Highlights


Saturday, 6 October Room

Lleida/Tarragona

Chair: Riccardo Lencioni, Pisa (Italy)

• Clinical guidelines - The consensus opinion of experts as regard to

the role of CEUS modality in liver imaging

Riccardo Lencioni, Pisa (Italy)

• STIC study for focal liver lesion diagnosis – Take-home messages from

a large multicenter clinical trial using CEUS in comparison to MDCT and

CEMRI

François Tranquart, Tours (France)

• The use of CEUS during liver surgery – Its impact on operative outcome

Guido Torzilli, Milan (Italy)

A light lunch will be provided.

Industry Symposium (Bracco) Focal liver lesions - The key role of contrast-enhanced UltraSound (CEUS) modality for diagnosis and early assessment of treatment efficacy

13.00 - 15.00

Contact Us

International Liver Cancer Association

(ILCA)

Global Headquarters

Avenue de Tervueren, 300

B-1150 Brussels – Belgium

Tel: +32 (0)2 789-2345

Fax: +32 (0)2 743-1550

Email: [email protected]

www.ilca-online.org

The International Liver Cancer Association (ILCA) aspires towards advancing research inthe pathogenesis, prevention, and treatment of liver cancer.

MissionThe International Liver Cancer Association (ILCA) promotes novel pathogenic, diagnosticand therapeutic interventions for liver cancer by taking a transversal approach toresearch and bringing together scientists, physicians and allied professionals from allinterrelated fields.

ValuesThe International Liver Cancer Association (ILCA):

• Is committed to promoting basic, clinical, translational, multi-disciplinary andmulti-national liver cancer research, including the development of clinical trials

• Fosters, encourages and facilitates scientific exchange and dissemination ofknowledge

• Strives to educate physicians, scientists, allied healthcare professionals and thegeneral public at large

• Will educate international and national health authorities on the diagnosis,prevention and management of liver cancer

• Values collaboration with other learned societies, governmental organizations,professional associations, groups, institutions and individuals who contribute toprogress in the field.

ILCA is the only international organization devoted exclusively to liver cancer researchfor experts from all related disciplines.

Executive CommitteePresident

Jordi Bruix (Spain)

Executive Secretary

Josep M Llovet (Spain/USA)

Treasurer

Peter Galle (Germany)

Council

Nelson Fausto (USA)

Snorri Thorgeirsson (USA)

Riccardo Lencioni (Italy)

Pierre-Alain Clavien (Switzerland)

Vincenzo Mazzaferro (Italy)

Masamichi Kojiro (Japan)

ILCA’s Interim Governing Board

www. i lca-on l ine .org

METHOD OF PAYMENT (Please check ■■✔ and provide all information requested)

■■ Wire Transfer (as a reference please include the applicant’s name on the transfer)

To the attention of MCI Benelux/ILCAAccount# 363-0098456-41Bank INGBIC/Swift# BBRUBEBBIBAN# BE88 363 0098456 41

■■ Check Number I__I__I__I__I__I__I__I__I__I__I__I__I DATED (month/day/year) ______ / ______ / ______

Membership fee ________________________ + processing fee ________________________

■■ Credit Card ■■ American Express ■■ MasterCard ■■ Visa

Card Number I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__I__IExpires ______ / ______ Name of Card Holder (as it appears on the card) ________________________________________________

Signature of Card Holder

PLEASE MAIL OR FAX THE COMPLETED FORM AND SUPPORTING MATERIALS TO:

International Liver Cancer Association (ILCA) - Attn: Francesca Rollo Global Headquarters - Avenue de Tervueren 300 - B-1150 Brussels - Belgium Tel: +32-2-743 4447 - Fax: +32-2-743 1550 Email: [email protected]

TO LEARN MORE ABOUT ILCA VISIT:

www.ilca-online.org

PLEASE COMPLETE THE APPLICATION FORM IN CAPITAL LETTERS.

PERSONAL DETAILS (Please complete all sections)

Name . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . ITITLE (Prof., Dr., etc.) FIRST (GIVEN) NAME MIDDLE INITIAL LAST (FAMILY) NAME DOCTORAL-LEVEL DEGREE(S)

Position . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Institution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Street / Box # . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . City . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Zip / Postal Code . . . . . . . . . . . . . . . . . . . State / Province . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Country. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Tel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Email . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Web Site . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Date of Birth (month/date/year) ______ / ______ / ______

Applicant's Signature

PROFESSIONAL ACTIVITY (Please check ■■✔ all that apply)

■■ Administrator ■■ Basic Researcher ■■ Clinical Researcher ■■ Retired ■■ Trainee ■■ Allied Health Professional ■■ Clinical Practitioner ■■ Industry Representative ■■ Teacher/Educator ■■ Other (please specify) _________________

DISCIPLINE INTEREST (Please check ■■✔ all that apply)

■■ Basic Research ■■ Hepatology ■■ Oncology ■■ Surgery/Transplantation■■ Epidemiology ■■ Internal Medicine ■■ Pathology ■■ Other (please specify) ___________________________________

■■ Gastroenterology ■■ Molecular Biology ■■ Radiology/Interventional Oncology

PRIMARY PRACTICE /RESEARCH SETTING (Please check ■■✔ all that apply)

Clinical Research/Practice: ■■ Private Practice ■■ Private Institution ■■ Academic Institution/University ■■ Government Institution/Agency

Basic Research/Practice: ■■ Private Institution/Corporation ■■ Academic Institution/University ■■ Government Institution/Agency

MEMBER CATEGORY, FEES & SUPPORTING DOCUMENTS (membership valid for the calendar year 1 January to 31 December 2007)

■■ Regular �Fee: 50 Euro (scientist / physician working in fields related to liver cancer who has contributed knowledge to the field).

Please provide these supporting documents: ● Letter of support from Founding Member ● Proof of publication of at least 2 papers with an Impact Factor according to the last ISI Web of Knowledge

■■ Trainee �Fee: 25 Euro (scientist / physician in training and certified by his/her training program director).

Please provide these supporting documents: ● Brief bio-sketch ● Letter of support from training program director or a Founding Member

■■ Associate �Fee: 25 Euro (allied health professionals involved in liver cancer research and/or practice).

Please provide these supporting documents: ● Brief bio-sketch ● Letter of support from a Founding Member ● Statement of commitment to liver cancer research/practice

■■ Emeritus �Fee: 50 Euro (scientist / physician meeting Regular member requirements, but who is retired from full-time employment).

Please provide these supporting documents: ● Brief bio-sketch ● Proof of publication of at least 2 papers with an Impact Factor

■■ Voluntary Donation (to ILCA for the development of its professional activities) �Amount: ................... Euro

Date post:	21-Jun-2018
Category:	Documents
Upload:	tranhuong
View:	215 times
Download:	0 times

ILCA’s First Annual Conference · New York, United States ... Enrique Lopez Hänninen2, Birgit...

Documents